항혈우병인자약 시장 규모 : 제품별, 용도별, 지역별, 범위 및 예측

Antihemophilic Factor Drug Market Size and Forecast

Antihemophilic Factor Drug Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

Antihemophilic factor drug is used to treat and control severe bleeding spells in patients with a bleeding problem. Increasing awareness among people and growing rare disorders among people across the globe is a significant problem for the healthcare field is the factor driving the market growth of the Antihemophilic Factor Drug Market. The Global Antihemophilic Factor Drug Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Antihemophilic Factor Drug Market Definition

Anti-hemophilia factor drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to stop bleeding. People with normal factor VIII levels are at increased risk of injury, post-surgery bleeding, and factor VIII bleeding in the body, also known as an anti-hemophilia factor. This product temporarily replaces lost factor VIII. A protein is usually present to help blood clots and stop bleeding. The medicine is usually given by intravenous injection for at least 5-10 minutes or as directed by the doctor. Depending on your dose and patient response, the drug may need to be given more slowly over time. After receiving this medicine for the first time at a hemophilia treatment center or hospital, some patients can self-administer this medicine at home. The drugs and solutions used for mixing were refrigerated. After adding the resolution to the powder, some brands of this drug may need to shake the vial for 10-15 seconds before gently rotating the vial to dissolve the powder completely. Ask your pharmacist about the correct combination of the medicines. Visually inspect for particulate matter or discoloration before using this product.

Global Antihemophilic Factor Drug Market Overview

The primary factor driving the market growth is the increasing number of rare disorder cases among people is the factor driving the market growth. This drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to stop bleeding. People at the general factor VIII level are at increased risk of injury / post-surgery and internal bleeding. This product contains Human Factor VIII, also known as an anti-hemophilia factor. This product temporarily replaces lost element VIII and a protein usually present in the blood to help blood clots and stop bleeding. Increasing awareness of such rare diseases among the population and government involvement in preventing and managing these life-threatening diseases are key factors behind the estimated growth of the antihemophilic drug market. In addition, increased investment by leading pharmaceutical companies in the research and development of new treatments for hemophilia is driving market expansion at an alarming rate.

Careful screening of blood donors, a unique manufacturing process, and many tests have been used to reduce this risk, but the risk of infection with this drug is minimal, limiting the market growth of the Antihemophilic factor Drug Market.

Global Antihemophilic Factor Drug Market: Segmentation Analysis

The Global Antihemophilic Factor Drug Market is segmented on the basis of Product, Application, and Geography.

Antihemophilic Factor Drug Market by Product

• 250 IU
• 500 IU
• 1000 IU
• 1500 IU
• 2000 IU
• 3000 IU
• 4000 IU
• Other potencies

Based on Product, the market is segmented into 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU, 3000 IU, 4000 IU and Other potencies.

Antihemophilic Factor Drug Market by Application

• Adult
• Pediatric

Based on the Application, the Adult segment holds a large number of shares in the market because the low risk for hypersensitivity reactions increases cases of disorders in adult ages peoples, which is the factor that boosts the market growth of the Antihemophilic factor Drug Market.

Antihemophilic Factor Drug Market by Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the North American region holds a large number of shares in the market because of the increasing number of cases in the region. The existence of key players in the region is the factor that propels the market growth of the Antihemophilic factor Drug Market.

Key Players

The "Global Antihemophilic Factor Drug Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are

Bayer, Shire, Novo Nordisk, Pfizer, Grifols, CSL Behring, Sanofi, Cigna, Octapharma, and GC Pharma.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 250 IU
• 5.3 500 IU
• 5.4 1000 IU
• 5.5 1500 IU
• 5.6 2000 IU
• 5.7 3000 IU
• 5.8 4000 IU
• 5.9 Other potencies

6 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Adult
• 6.3 Pediatric

7 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL ANTIHEMOPHILIC FACTOR DRUG MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Bayer
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Shire
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Novo Nordisk
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Pfizer
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Grifols
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 CSL Behring
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Development
• 9.7 Sanofi
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Cigna
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Octapharma
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Development
• 9.10 GC Pharma
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Development

10 Related Reports